REMINDER: Our focusIR Investor Webinar takes place TONIGHT with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBrooks Macdonald Regulatory News (BRK)

Share Price Information for Brooks Macdonald (BRK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,965.00
Bid: 1,980.00
Ask: 2,040.00
Change: -47.50 (-2.36%)
Spread: 60.00 (3.03%)
Open: 1,965.00
High: 1,965.00
Low: 1,965.00
Prev. Close: 2,012.50
BRK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director appointment

16 Feb 2023 07:00

RNS Number : 0700Q
Brooks Macdonald Group PLC
16 February 2023
 

16 February 2023

 

BROOKS MACDONALD GROUP PLC

 

Director appointment

 

Brooks Macdonald Group plc ("The Group", "Brooks Macdonald") is pleased to announce the appointment of James Rawlingson as Non-Executive Director effective 2 March 2023. James will in due course assume the role of Chairman of the Audit Committee, subject to regulatory approval.

 

James currently serves as Chairman of the Audit and Risk Committee at Citibank UK, Chairman of the Audit and Risk Assurance Committee at the Foreign Office's executive agency Wilton Park, and Chairman of the Board at Novai Ltd. In his executive career James has held senior positions at Coutts, UBS Wealth, Charles Stanley plc and Arix Bioscience plc.

 

Commenting on the appointment, Acting Chairman Richard Price said: "I am delighted that James is joining the Board. James has had an extensive career and his sector experience will provide valuable insight as the Company continues towards its strategic goals."

 

AIM disclosures

 

During the five years immediately preceding the date of this announcement, James Hedley Rawlingson, who is 55 years old, held the following directorships:

 

Current

 

Citibank UK Limited

Wilton Park (an Arm's Length Body of the British Foreign, Commonwealth & Development Office)

Novai Limited

 

Previous

 

Next Gen PPE limited

Arix Bioscience Holdings Limited

Arix Bioscience plc

Arthurian Life Sciences GP Limited

Als SPV Limited

Arix Capital Management Limited

Arthurian Life Sciences SPV GP Limited

 

There is no further information to be disclosed pursuant to Schedule Two Part (g) of the AIM Rules for Companies.

 

Enquiries to:

Brooks Macdonald Group plc

Andrew Shepherd, CEO

www.brooksmacdonald.com

020 7927 4816

 

Peel Hunt LLP (Nominated Adviser and Broker)

Paul Shackleton / Andrew Buchanan / John Welch

020 7418 8900

 

FTI Consulting

Laura Ewart / Katherine Bell

brooksmacdonald@fticonsulting.com

07711 387 085 / 07976 870 961

 

Notes to editors

 

Brooks Macdonald Group plc, through its various subsidiaries, provides leading investment management services in the UK and internationally. The Group, which was founded in 1991 and began trading on AIM in 2005, had discretionary Funds under Management of £16.2 billion as at 31 December 2022.

 

Brooks Macdonald offers a range of investment management services to private high net worth individuals, pension funds, institutions, charities and trusts. The Group also provides financial planning as well as international investment management, and acts as fund manager to a range of onshore and international funds.

 

The Group has fifteen offices across the UK and Crown Dependencies including London, Birmingham, Cheltenham, East Anglia, Exeter, Leeds, Manchester, Nuneaton, Southampton, Tunbridge Wells, Scotland, Wales, Jersey, Guernsey and Isle of Man.

 

LEI: 213800WRDF8LB8MIEX37

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAUVSWROAUUAAR
Date   Source Headline
24th Oct 202310:03 amRNSDirector/PDMR Shareholding
13th Oct 20233:59 pmRNSDirector/PDMR Shareholding
12th Oct 202312:25 pmRNSForm 8.3 - Round Hill Music Royalty Fund Limited
12th Oct 20237:00 amRNSQuarterly Announcement of Funds under Management
10th Oct 202312:59 pmRNSForm 8.3 - Round Hill Music Royalty Fund Limited
9th Oct 202312:36 pmRNSForm 8.3 - Round Hill Music Royalty Fund Limited
6th Oct 202310:57 amRNSForm 8.3 - Round Hill Music Royalty Fund Limited
3rd Oct 20231:18 pmRNSForm 8.3 - Round Hill Music Royalty Fund Limited
3rd Oct 20231:15 pmRNSForm 8.3 - Ergomed PLC
2nd Oct 20231:26 pmRNSForm 8.3 - Round Hill Music Royalty Fund Limited
2nd Oct 20237:00 amRNSTotal Voting Rights
28th Sep 20231:27 pmRNSForm 8.3 - Round Hill Music Royalty Fund Limited
26th Sep 20231:01 pmRNSForm 8.3 - Round Hill Music Royalty Fund Limited
22nd Sep 20234:29 pmRNSNotice of AGM
22nd Sep 20231:00 pmRNSForm 8.3 - Round Hill Music Royalty Fund Limited
21st Sep 202312:06 pmRNSForm 8.3 - Round Hill Music Royalty Fund Limited
20th Sep 202310:41 amRNSForm 8.3 - Round Hill Music Royalty Fund Limited
19th Sep 202312:13 pmRNSDirector/PDMR Shareholding
14th Sep 20237:00 amRNSFinal Year Results for the year ended 30 June 2023
13th Sep 20237:00 amRNSEquity Development Investor Presentation
12th Sep 20231:06 pmRNSForm 8.3 - Round Hill Music Royalty Fund Limited
11th Sep 20232:04 pmRNSForm 8.3 - Round Hill Music Royalty Fund Limited
1st Sep 20233:32 pmRNSTotal Voting Rights
10th Aug 20234:36 pmRNSHolding(s) in Company
10th Aug 20232:44 pmRNSAdditional Listing
1st Aug 20239:00 amRNSTotal Voting Rights
13th Jul 20237:00 amRNSNotice of Full Year results
4th Jul 202311:50 amRNSHolding(s) in Company
3rd Jul 202310:10 amRNSTotal Voting Rights
27th Jun 202311:55 amRNSDirector/PDMR Shareholding
23rd Jun 20239:03 amRNSHolding(s) in Company
15th Jun 20237:00 amRNSDirectorate Change
8th Jun 202312:43 pmRNSBlock listing Interim Review
5th Jun 20239:59 amRNSDirector/PDMR Shareholding
1st Jun 20231:05 pmRNSTotal Voting Rights
22nd May 202311:50 amRNSBlock Listing Application
12th May 20238:55 amRNSDirector/PDMR Shareholding
11th May 202310:55 amRNSForm 8.3 - US Solar Fund plc
10th May 20233:38 pmRNSDirector/PDMR Shareholding
10th May 202311:13 amRNSForm 8.3 - US Solar Fund plc
9th May 20239:25 amRNSHolding(s) in Company
2nd May 20237:00 amRNSTotal Voting Rights
27th Apr 20232:15 pmRNSForm 8.3 - US Solar Fund plc
21st Apr 202310:31 amRNSDirector/PDMR Shareholding
13th Apr 202311:06 amRNSForm 8.3 - US Solar Fund plc
13th Apr 20237:00 amRNSQuarterly Announcement of Funds under Management
6th Apr 202311:15 amRNSForm 8.3 - US Solar Fund plc
4th Apr 202310:53 amRNSForm 8.3 - US Solar Fund plc
3rd Apr 20231:28 pmRNSForm 8.3 - US Solar Fund plc
3rd Apr 20237:00 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.